Medicare Now Covers CAR T-Cell Therapy for Approved Cancers

A promising and expensive type of immunotherapy, called CAR T-cell therapy, is now covered by Medicare. This news may affect mesothelioma patients in the future. Chimeric antigen receptor T-cell, or CAR T-cell, therapy involves the laboratory reprogramming of a patient’s T cells, which are a type of white blood cell responsible for protecting the body against infection and disease. The T cells are genetically modified to better recognize and attack cancer. The U.S. Food and Drug Administration has approved the immunotherapy procedure for non-Hodgkin lymphoma and B-cell precursor acute lymphoblastic leukemia. It is still in the experimental phase for many other cancers, including mesothelioma, the rare cancer caused by asbestos exposure. Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center told The Mesothelioma Center at that CAR T-cell therapy will “change the paradigm of treating mesothelioma.” Adusumilli is the primary investigator of a phase I clinical trial testing the safety of different doses of modified T cells for patients with malignant pleural mesothelioma. The trial is estimated to conclude in April 2020. “We are seeing results now,” he said. “We are going in the right direction.” CAR-T for Mesothelioma Available Through Clinical Trials CAR T-cell therapy is estimated to cost between $375,000 and $475,000. Currently, that high price tag doesn’t apply to mesothelioma patients, who can only...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news

Related Links:

Authors: Higashihara T, Okada A, Nakamura Y, Saigusa H, Homma S, Matsumura M, Kusano T, Shimizu A, Takano H Abstract We performed a renal biopsy for nephrotic syndrome in a patient with squamous cell lung carcinoma, which can worsen the prognosis. Chemoradiation therapy was effective for the cancer and proteinuria; we thus inferred that the nephrotic syndrome had been closely associated with the carcinoma. A pathological analysis of the kidney showed monoclonality for λ chain, satisfying the diagnostic criteria of proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID); however, con...
Source: Internal Medicine - Category: Internal Medicine Tags: Intern Med Source Type: research
ConclusionsThe results of this study showed that lung volume changes were not a cause for concern in breast cancer patients. There are three reasons to support this conclusion. Lung volume changes and percentage reductions in LVP for each Gy increase of MLD and each percentage increase of V20 in each lobe were small; patients were asymptomatic during the follow-up period; and LVP showed partial improvements after 6 months.
Source: Reports of Practical Oncology and Radiotherapy - Category: Cancer & Oncology Source Type: research
ConclusionUsing robust optimization for skin flash in breast IMRT planning is feasible. Further investigation is warranted to confirm the clinical effectiveness of this novel approach.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research
AbstractThe use of conventional chemotherapy in the treatment of cancer has been restricted by the lack of cell specificity, which causes toxicity regarding healthy cells resulting in limiting side effects responsible for low therapeutic efficiency. To overcome these drawbacks, the design of prodrugs has evolved and improved by covalently linking the drug through a degradable spacer. The use of these prodrugs as drug delivery systems, which are able to inactivate the drug during its biodistribution to specifically deliver the drug to its target, is an important breakthrough in cancer therapy. This strategy consisting in th...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
ConclusionsThe exposure –response analysis suggested that intermittent 7-day veliparib 120 mg BID dosing in a 21-day cycle provided additional efficacy without meaningfully impacting the safety and tolerability when co-administered with carboplatin and paclitaxel in patients with BRCA-deficient breast cancer. A higher d ose of veliparib is unlikely to provide greater benefit in this combination in patients with BRCA-deficient recurrent or metastatic breast cancer.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
AbstractThioredoxin (Trx), thioredoxin reductase (TrxR), and NADPH are key members of the Trx system that is involved in redox regulation and antioxidant defense. In recent years, several researchers have provided information about the roles of the Trx system in cancer development and progression. These reports indicated that many tumor cells express high levels of Trx and TrxR, which can be responsible for drug resistance in tumorigenesis. Inhibition of the Trx system may thus contribute to cancer therapy and improving chemotherapeutic agents. There are now a number of effective natural and synthetic inhibitors with chemo...
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Authors: Fistarol F, De Stavola L, Fincato A, Bressan E Abstract The aim of this study is to evaluate the anatomical characteristics of the posterior region of the mandible and their surgical relevance related to bone harvesting procedures. Fifty retromolar cone beam computed tomography scans were analyzed considering the donor site anatomies. For each site, linear measurements were taken of cross-sectional scans to record perpendicular distances between the mandibular canal (MC) and the vestibular and crestal bone walls. Data showed that the distance from the MC to the vestibular bone wall is lower in the ramus ar...
Source: International Journal of Periodontics and Restorative Dentistry - Category: Dentistry Tags: Int J Periodontics Restorative Dent Source Type: research
Date: Wednesday, 10 16, 2019; Speaker: Rowan Chlebowski, MD, PhD, Chief and Senior Investigator, Harbor-UCLA Medical Center; Building: Building 10 (Clinical Center); Lipsett Amphitheater
Source: NIH Calendar of Events - Category: American Health Source Type: events
Date: Thursday, 11 14, 2019; Speaker: Ulrike Lorenz, Ph.D., Associate Professor, Dept. of Microbiology, Immunology, and Cancer Biology, University of Virginia; Building: Building 6B; 4B-429
Source: NIH Calendar of Events - Category: American Health Source Type: events
ConclusionMTV and TLG reflecting the metabolic tumor burden can predict OS in patients with advanced lung adenocarcinoma.ResumenObjetivoEl presente estudio evalúa el valor pronóstico de los parámetros metabólicos relacionados con el tumor primario en el 18F-FDG PET/TC pretratamiento en pacientes con adenocarcinoma pulmonar en fase avanzada.Materiales y métodosEste estudio retrospectivo incluyó 258 pacientes con adenocarcinoma pulmonar en fase avanzada a los que se les realizó un escáner PET/TC del pretratamiento y para quienes estaba disponible el receptor del factor ...
Source: Revista Espanola de Medicina Nuclear e Imagen Molecular - Category: Nuclear Medicine Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Child Development | Children | Clinical Trials | Environmental Health | Food and Drug Administration (FDA) | Gene Therapy | Genetics | Government | Health Management | Hodgkin's Disease | Hospitals | Immunotherapy | Laboratory Medicine | Leukemia | Lymphoma | Medicaid | Medicare | Mesothelioma | Non-Hodgkin's Lymphoma | PET Scan | Radiation Therapy | Study